Apogee Licenses ABC294640 to RedHill Biopharma – March 31, 2015

Apogee has successfully licensed exclusive rights to ABC294640 to RedHill Biopharma.  Apogee is thrilled to pass this promising drug into the capable, experienced hands of RedHill for late stage clinical development.

http://globenewswire.com/news-release/2015/03/31/720531/10126995/en/RedHill-Biopharma-Acquires-Phase-II-First-in-Class-Oral-Small-Molecule-SK2-Inhibitor-From-Apogee-Biotech.html

Powered by THE BRAVO GROUP & ARCHODA: CREATE SOMETHING UNIQUE